State Key Laboratory of Systems Medicine for Cancer, Renji-Med X Clinical Stem Cell Research Center, Ren Ji Hospital, Shanghai Cancer Institute, School of Medicine, Shanghai Jiao Tong University, Shanghai, 200127, China.
Pediatric Translational Medicine Institute, Department of Hematology & Oncology, Shanghai Children's Medical Center, School of Medicine, Shanghai Jiao Tong University, National Health Committee Key Laboratory of Pediatric Hematology & Oncology, Shanghai, 200127, China.
Adv Sci (Weinh). 2024 Aug;11(29):e2400023. doi: 10.1002/advs.202400023. Epub 2024 Jun 3.
The factors driving glioma progression remain poorly understood. Here, the epigenetic regulator TRIM24 is identified as a driver of glioma progression, where TRIM24 overexpression promotes HRas anaplastic astrocytoma (AA) progression into epithelioid GBM (Ep-GBM)-like tumors. Co-transfection of TRIM24 with HRas also induces Ep-GBM-like transformation of human neural stem cells (hNSCs) with tumor protein p53 gene (TP53) knockdown. Furthermore, TRIM24 is highly expressed in clinical Ep-GBM specimens. Using single-cell RNA-sequencing (scRNA-Seq), the authors show that TRIM24 overexpression impacts both intratumoral heterogeneity and the tumor microenvironment. Mechanically, HRas activates phosphorylated adaptor for RNA export (PHAX) and upregulates U3 small nucleolar RNAs (U3 snoRNAs) to recruit Ku-dependent DNA-dependent protein kinase catalytic subunit (DNA-PKcs). Overexpressed TRIM24 is also recruited by PHAX to U3 snoRNAs, thereby facilitating DNA-PKcs phosphorylation of TRIM24 at S767/768 residues. Phosphorylated TRIM24 induces epigenome and transcription factor network reprogramming and promotes Ep-GBM-like transformation. Targeting DNA-PKcs with the small molecule inhibitor NU7441 synergizes with temozolomide to reduce Ep-GBM tumorigenicity and prolong animal survival. These findings provide new insights into the epigenetic regulation of Ep-GBM-like transformation and suggest a potential therapeutic strategy for patients with Ep-GBM.
导致神经胶质瘤进展的因素仍知之甚少。在这里,鉴定出表观遗传调节剂 TRIM24 是神经胶质瘤进展的驱动因素,其中 TRIM24 过表达促进 HRas 间变性星形细胞瘤 (AA) 进展为上皮样 GBM (Ep-GBM)-样肿瘤。TRIM24 与 HRas 的共转染也诱导了 TP53 基因敲低的人神经干细胞 (hNSC) 的 Ep-GBM 样转化。此外,TRIM24 在临床 Ep-GBM 标本中高度表达。通过单细胞 RNA 测序 (scRNA-Seq),作者表明 TRIM24 过表达既影响肿瘤内异质性又影响肿瘤微环境。在机制上,HRas 激活 RNA 输出的磷酸化衔接蛋白 (PHAX),上调 U3 小核仁 RNA (U3 snoRNAs),从而招募 Ku 依赖性 DNA 依赖性蛋白激酶催化亚基 (DNA-PKcs)。过表达的 TRIM24 也被 PHAX 招募到 U3 snoRNAs,从而促进 DNA-PKcs 在 S767/768 残基上磷酸化 TRIM24。磷酸化的 TRIM24 诱导表观基因组和转录因子网络重编程,并促进 Ep-GBM 样转化。用小分子抑制剂 NU7441 靶向 DNA-PKcs 与替莫唑胺联合使用,可降低 Ep-GBM 肿瘤发生能力并延长动物存活时间。这些发现为 Ep-GBM 样转化的表观遗传调控提供了新的见解,并为 Ep-GBM 患者提供了一种潜在的治疗策略。